PORT-2

N/A

Report date: 2025/02/19 10:13:51
NME

Base Information

Drug NamePORT-2
Drug Alias NameThreitolceramide-6IMM-60IMM60ThrCer-6PORT-2 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actioninvariant natural killer T cell activators
TargetsUpdating
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomSpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of OxfordLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesPortage Biotech IncUniversity Of Oxford
Inactive CompaniesiOx Therapeutics Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A